Log in

Relevant bibliographies by topics / 004.056.523:57.087.1 (043.3)

Contents

Journal articles

Academic literature on the topic '004.056.523:57.087.1 (043.3)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '004.056.523:57.087.1 (043.3).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "004.056.523:57.087.1 (043.3)"

1

Giovanelli, Nicola, Paolo Taboga, Enrico Rejc, Bostjan Simunic, Guglielmo Antonutto, and Stefano Lazzer. "Effects of an Uphill Marathon on Running Mechanics and Lower-Limb Muscle Fatigue." International Journal of Sports Physiology and Performance 11, no. 4 (2016): 522–29. http://dx.doi.org/10.1123/ijspp.2014-0602.

Full text

Abstract:

Purpose:To investigate the effects of an uphill marathon (43 km, 3063-m elevation gain) on running mechanics and neuromuscular fatigue in lower-limb muscles.Methods:Maximal mechanical power of lower limbs (MMP), temporal tensiomyographic (TMG) parameters, and muscle-belly displacement (Dm) were determined in the vastus lateralis muscle before and after the competition in 18 runners (age 42.8 ± 9.9 y, body mass 70.1 ± 7.3 kg, maximal oxygen uptake 55.5 ± 7.5 mL · kg−1 · min−1). Contact (tc) and aerial (ta) times, step frequency (f), and running velocity (v) were measured at 3, 14, and 30 km and

APA, Harvard, Vancouver, ISO, and other styles

2

Ramiro, S., D. Poddubnyy, P. J. Mease, et al. "POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 358–59. http://dx.doi.org/10.1136/annrheumdis-2023-eular.831.

Full text

Abstract:

BackgroundA history of enthesitis or peripheral arthritis has been reported in >30% of patients (pts) with axial spondyloarthritis (axSpA),[1]both of which contribute to disease burden. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated efficacy in phase 3 parallel studies in pts with non-radiographic (nr-)axSpA (BE MOBILE 1) and radiographic axSpA (r-axSpA i.e. ankylosing spondylitis; BE MOBILE 2).[2,3]ObjectivesTo evaluate the impact of BKZ on the main peripheral manifestations of axSpA, to Week (Wk) 52.Meth

APA, Harvard, Vancouver, ISO, and other styles

3

Deodhar, A., D. Van der Heijde, L. S. Gensler, et al. "POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 772–73. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2416.

Full text

Abstract:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in a phase 2b study in patients (pts) with active ankylosing spondylitis.1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active non-radiographic axial spondyloarthritis (nr-axSpA) up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 1.MethodsBE MOBILE 1 (NCT03928704) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were

APA, Harvard, Vancouver, ISO, and other styles

4

Habib, Alma, Abdullah Mohammad Khan, Mehak M. Laharwal, et al. "A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment." Blood 144, Supplement 1 (2024): 7037. https://doi.org/10.1182/blood-2024-209283.

Full text

Abstract:

Introduction: In the pivotal clinical trial (MajesTEC-1), teclistamab-cqyv (Tec), a bispecific B-cell maturation antigen (BCMA)-directed T-cell engager, showed promising efficacy in terms of overall response rate and duration of response in heavily pretreated relapsed refractory multiple myeloma (RRMM); however, patients (pts) with an estimated glomerular filtration rate of &lt;40mL/min were excluded. The effect of Tec in treatment of RRMM in pts with baseline renal impairment (RI) is limited. Herein, we evaluated the impact of baseline RI on development of toxicities and outcomes in RRMM

APA, Harvard, Vancouver, ISO, and other styles

5

Van der Heijde, D., X. Baraliakos, M. Dougados, et al. "OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 12–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2441.

Full text

Abstract:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in patients (pts) with active ankylosing spondylitis (AS).1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active AS up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 2.MethodsBE MOBILE 2 (NCT03928743) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, met modified New York criteria

APA, Harvard, Vancouver, ISO, and other styles

6

Hunault-Berger, Mathilde, Yves Gruel, Jean-Luc Harousseau, et al. "Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study." Blood 104, no. 11 (2004): 4486. http://dx.doi.org/10.1182/blood.v104.11.4486.4486.

Full text

Abstract:

Abstract The incidence of AT and Fg deficiency and of thrombotic and bleeding events after Asp has been well evaluated in children with ALL, but little is known in adults. In this study, the incidence of these events and the use of coagulation supportive treatments was evaluated in 214 adult patients with ALL (n= 191) or LBL (n=23) included in the GOELAL02 trial (Blood 2004, in press). The induction therapy included steroids (40 mg/m2/d d1-21), vincristine (2 mg d1, 8, 15, 22), idarubicine (5 mg/m2 d1, 8,15, 22) and Asp (7500 UI/m2 d10, 13, 16, 19, 22, 25) delivered through a central venous ac

APA, Harvard, Vancouver, ISO, and other styles

7

Hens, Luc, Nguyen An Thinh, Tran Hong Hanh, et al. "Sea-level rise and resilience in Vietnam and the Asia-Pacific: A synthesis." VIETNAM JOURNAL OF EARTH SCIENCES 40, no. 2 (2018): 127–53. http://dx.doi.org/10.15625/0866-7187/40/2/11107.

Full text

Abstract:

Climate change induced sea-level rise (SLR) is on its increase globally. Regionally the lowlands of China, Vietnam, Bangladesh, and islands of the Malaysian, Indonesian and Philippine archipelagos are among the world’s most threatened regions. Sea-level rise has major impacts on the ecosystems and society. It threatens coastal populations, economic activities, and fragile ecosystems as mangroves, coastal salt-marches and wetlands. This paper provides a summary of the current state of knowledge of sea level-rise and its effects on both human and natural ecosystems. The focus is on coastal urban

APA, Harvard, Vancouver, ISO, and other styles

8

Bulkova, Veronika, Martin Fiala, Dan Wichterle, et al. "Abstract P302: Improvement of Quality of Life and Socioeconomic Parameters After Ablation is Equal in Patients With Paroxysmal and Persistent Atrial Fibrillation." Circulation: Cardiovascular Quality and Outcomes 4, suppl_1 (2011). http://dx.doi.org/10.1161/circoutcomes.4.suppl_1.ap302.

Full text

Abstract:

Background: Because patients with persistent atrial fibrillation (AF) are perceived to have more ‘stable’ symptoms, it is unclear if their long-term resource use and health status improves after treatment with radiofrequency catheter ablation (RFA). Methods: In a large, multicentre-study, prospective cohort of 472 consecutive patients undergoing RFA, we examined the success rate, resource use, and quality of life (QoL) of patients with paroxysmal and persistent AF at baseline and 18 months after RFA. QoL was assessed using the EQ-5D questionnaire. Results: The mean age of the study cohort was

APA, Harvard, Vancouver, ISO, and other styles

9

Du, Mengxi, and Fang Fang Zhang. "Dietary Supplement Use Among Adult Cancer Survivors in the United States." FASEB Journal 31, S1 (2017). http://dx.doi.org/10.1096/fasebj.31.1_supplement.168.6.

Full text

Abstract:

BackgroundMany cancer patients initiated supplement use after cancer diagnosis and yet the effect of supplement use on survival has not been established. The trend of and factors associated with dietary supplement use in cancer survivors warrant further investigation.MethodsWe examined the trend of dietary supplemental use in 1,902 adult cancer survivors who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2012, and compared the frequency of supplement use in cancer survivors to that of 3,804 individuals with no history of cancer who were matched to th

APA, Harvard, Vancouver, ISO, and other styles

10

Dolomatov, S.I., та W. Zukow. "Эпигенетика почек = Kidneys epigenetics". 7 липня 2019. https://doi.org/10.5281/zenodo.3270754.

Full text

Abstract:

<strong>Dolomatov S.I., Zukow W. </strong><strong>Эпигенетика почек</strong><strong> = Kidney</strong><strong>s</strong><strong> epigenetics</strong><strong>. </strong><strong>RSW. Radom,</strong><strong> 144 </strong><strong>p. ISBN </strong><strong>9780359774524</strong><strong>.</strong><strong> DOI </strong><strong>http://dx.doi.org/10.5281/zenodo.3270699</strong><strong> PBN Poland </strong><strong>https://pbn.nauka.gov.pl/sedno-webapp/works/917606</strong>           <strong>Radomska Szkoła Wyższa w Radomiu, Radom, Poland</strong>         &nbsp

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!